Tulsa Wealth Advisors INC Has $945,000 Stake in Medtronic PLC $MDT

Tulsa Wealth Advisors INC reduced its stake in shares of Medtronic PLC (NYSE:MDT) by 49.6% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 12,079 shares of the medical technology company’s stock after selling 11,865 shares during the period. Tulsa Wealth Advisors INC’s holdings in Medtronic were worth $945,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Anfield Capital Management LLC boosted its position in shares of Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after buying an additional 230 shares during the last quarter. Monetary Solutions Ltd bought a new stake in Medtronic during the fourth quarter worth $27,000. Acumen Wealth Advisors LLC purchased a new stake in Medtronic in the 4th quarter valued at $29,000. IAG Wealth Partners LLC purchased a new stake in Medtronic in the 2nd quarter valued at $30,000. Finally, Imprint Wealth LLC bought a new position in Medtronic during the 3rd quarter valued at $31,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This represents a 10.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.26% of the stock is currently owned by insiders.

Medtronic Trading Down 1.8%

Shares of Medtronic stock opened at $92.45 on Friday. The firm has a market cap of $118.33 billion, a PE ratio of 24.79, a P/E/G ratio of 2.52 and a beta of 0.55. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The stock has a fifty day moving average price of $84.12 and a 200-day moving average price of $86.01.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. The company had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Friday, September 25th. Medtronic’s payout ratio is presently 77.21%.

Analyst Upgrades and Downgrades

MDT has been the topic of a number of analyst reports. Wall Street Zen raised shares of Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Robert W. Baird dropped their price target on shares of Medtronic from $93.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Leerink Partners cut their price target on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating on the stock in a report on Thursday, June 4th. Rothschild & Co Redburn reduced their price objective on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research report on Friday, June 5th. Finally, Evercore set a $105.00 price objective on shares of Medtronic in a research note on Monday, July 6th. Eighteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $98.83.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).